PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50122C00007Pandflu and — Arcturus Therapeutics Inc

Arcturus Therapeutics Inc holds — across 1 federal awards. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. PoP ended Aug 20, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Arcturus Therapeutics Inc

Recipient

Aug 20, 2026

PoP end

$63.2M

Obligated

541714

NAICS

AN14

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Arcturus Therapeutics Inc — $90

Contract facts

NONE

Contract number75A50122C00007

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentArcturus Therapeutics Inc

UEIE3MFDBN4L3J9

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN14

Place of performanceSAN DIEGO, CA

PoP end (current)Aug 20, 2026

Obligated$63.2M

PROCURE A PANDEMIC INFLUENZA VACCINE (PANDFLU) AND A QUADRIVALENT SEASONAL INFLUENZA VACCINE (QSFLU) is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Arcturus Therapeutics Inc. Estimated value $63.2M ($63.2M obligated). Current period of performance ends Aug 20, 2026. Last award drew 1 bidder. Place of performance: SAN DIEGO, CA.

PROCURE A PANDEMIC INFLUENZA VACCINE (PANDFLU) AND A QUADRIVALENT SEASONAL INFLUENZA VACCINE (QSFLU)

Recompete timing

Public

● Past PoP end (18 days ago)

Current PoP ended Aug 20, 2026 (18 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Arcturus Therapeutics Inc — — obligated across 1 awards (firm-wide, all agencies).

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50122C00007?

75A50122C00007 (Pandflu and) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $63.2M, currently held by Arcturus Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50122C00007?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50122C00007 to Arcturus Therapeutics Inc.

Who is the incumbent on 75A50122C00007?

Arcturus Therapeutics Inc is the incumbent with — across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 20, 2026.

When does Arcturus Therapeutics Inc’s 75A50122C00007 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 20, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50122C00007 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Mar 20, 2026